There was a large meta-analysis recently published that compared the efficacy of abiraterone acetate (Zytiga), enzalutamide (Xtandi), cabazitaxel (Jevtana) and Radium-223 (Xofigo) in the treatment of castration-resistant, docetaxel-resistant metastatic prostate cancer.
The authors compared the overall survival (OS) and time to PSA progression among abiraterone acetate, enzalutamide, cabazitaxel and Radium-223. Overall survival (OS) was a primary endpoint in the entire population of men. Additional secondary endpoints included measures of the quality of life, pretreated with 1 or 2 courses of chemotherapy, and time to PSA progression.
The analysis showed there was no significant difference in OS among abiraterone acetate, enzalutamide, cabazitaxel and radium 223 treatment in neither the entire population nor all the subgroups of men. The men receiving Enzalutamide (Xtandi) had significantly better than abiraterone acetate, cabazitaxel or radium-223 in time to PSA progression.
Since there doesn’t seem to be any significant difference in efficacy among these drugs in the treatment of castration-resistant, docetaxel-resistant, metastatic prostate cancer, the safety of the treatment, patient's compliance and costs should be the best criteria to guide choice in clinical practice.
Joel T. Nowak, MA, MSW wrote this Post. Joel is the CEO/Executive Director of Cancer ABCs. He is a Cancer Thriver diagnosed with five primary cancers - Thyroid, Metastatic Prostate, Renal, Melanoma, and the rare cancer Appendiceal cancer.